Abstract

Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor TLE3 conferred resistance to AR antagonists apalutamide and enzalutamide. Genes differentially expressed upon TLE3 loss share AR as the top transcriptional regulator, and TLE3 loss rescued the expression of a subset of androgen-responsive genes upon enzalutamide treatment. GR expression was strongly upregulated upon AR inhibition in a TLE3-negative background. This was consistent with binding of TLE3 and AR at the GR locus. Furthermore, GR binding was observed proximal to TLE3/AR-shared genes. GR inhibition resensitized TLE3KO cells to enzalutamide. Analyses of patient samples revealed an association between TLE3 and GR levels that reflected our findings in LNCaP cells, of which the clinical relevance is yet to be determined. Together, our findings reveal a mechanistic link between TLE3 and GR-mediated resistance to AR inhibitors in human prostate cancer.

Data availability

Data for Figure 1 (CRISPR resistance screen) is provided (source data file for Figure 1).Data for Figure 2 (RNA-seq) have been deposited in GEO under accession code GSE130246.Data (ChIP-seq) for Figure 3 and 4 is publicly available (GSE94682).Data for Figure 5C is the TCGA dataset (publicly available).

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Sander AL Palit

    Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands
    For correspondence
    s.palit@nki.nl
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2487-4311
  2. Daniel Vis

    Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  3. Suzan Stelloo

    Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  4. Cor Lieftink

    Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  5. Stefan Prekovic

    Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  6. Elise Bekers

    Division of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  7. Ingrid Hofland

    Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  8. Tonći Šuštić

    Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  9. Liesanne Wolters

    Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  10. Roderick Beijersbergen

    Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  11. Andries M Bergman

    Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  12. Balázs Győrffy

    TTK Cancer Biomarker Research Group, Institute of Enzymology, Semmelweis University, Budapest, Hungary
    Competing interests
    No competing interests declared.
  13. Lodewyk FA Wessels

    Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    No competing interests declared.
  14. Wilbert Zwart

    Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    Wilbert Zwart, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9823-7289
  15. Michiel S van der Heijden

    Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands
    For correspondence
    ms.vd.heijden@nki.nl
    Competing interests
    No competing interests declared.

Funding

KWF Kankerbestrijding (NKI2014-7080)

  • Michiel S van der Heijden

KWF Kankerbestrijding (NKI2014-7080)

  • Andries M Bergman

KWF Kankerbestrijding (NKI2014-7080)

  • Wilbert Zwart

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2019, Palit et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,460
    views
  • 421
    downloads
  • 28
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sander AL Palit
  2. Daniel Vis
  3. Suzan Stelloo
  4. Cor Lieftink
  5. Stefan Prekovic
  6. Elise Bekers
  7. Ingrid Hofland
  8. Tonći Šuštić
  9. Liesanne Wolters
  10. Roderick Beijersbergen
  11. Andries M Bergman
  12. Balázs Győrffy
  13. Lodewyk FA Wessels
  14. Wilbert Zwart
  15. Michiel S van der Heijden
(2019)
TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
eLife 8:e47430.
https://doi.org/10.7554/eLife.47430

Share this article

https://doi.org/10.7554/eLife.47430

Further reading

    1. Cancer Biology
    2. Medicine
    Patrick Brandt, Dawayne Whittington ... Rebekah L Layton
    Research Article

    A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.

    1. Cancer Biology
    Ke Ning, Yuanyuan Xie ... Ling Yu
    Research Article

    For traditional laboratory microscopy observation, the multi-dimensional, real-time, in situ observation of three-dimensional (3D) tumor spheroids has always been the pain point in cell spheroid observation. In this study, we designed a side-view observation petri dish/device that reflects light, enabling in situ observation of the 3D morphology of cell spheroids using conventional inverted laboratory microscopes. We used a 3D-printed handle and frame to support a first-surface mirror, positioning the device within a cell culture petri dish to image cell spheroid samples. The imaging conditions, such as the distance between the mirror and the 3D spheroids, the light source, and the impact of the culture medium, were systematically studied to validate the in situ side-view observation. The results proved that placing the surface mirror adjacent to the spheroids enables non-destructive in situ real-time tracking of tumor spheroid formation, migration, and fusion dynamics. The correlation between spheroid thickness and dark core appearance under light microscopy and the therapeutic effects of chemotherapy doxorubicin and natural killer cells on spheroids’ 3D structure was investigated.